Group 1 - The domestic equity market experienced fluctuations last week, with major indices showing a weekly change within 1% and an average daily trading volume around 1.1 trillion yuan [1] - The North Securities 50 Index reached a historical high after breaking through 1500 points but then showed significant adjustment [1] - The A-share technology growth sector showed signs of weakening, while the Hong Kong innovative drug sector performed well [1] Group 2 - China's innovative drug sector has rapidly developed in recent years, with the number of active innovative drugs developed by Chinese companies reaching 3,575 by the end of 2024, ranking first globally [1] - Approximately 31% of innovative drug candidate molecules introduced by large multinational pharmaceutical companies in 2024 are from China, a significant increase from 0% in 2019 [1] - In April, the added value of high-tech manufacturing above designated size grew by 10%, indicating a clear trend towards high-end industrial development [1] Group 3 - The Chinese economy has shown resilience against external shocks, with a year-on-year increase of 2.4% in total goods import and export from January to April [1] - The bond market experienced overall fluctuations, with long-term bonds performing slightly better than short-term ones, and credit bond yields generally declining [2] - The market's response to recent interest rate changes, including a 10 basis point rate cut, has been limited, with future observations focusing on changes in funding supply post-tax period [2]

Group 1 - The Hang Seng Index opened down 0.4%, with the Hang Seng Tech Index falling 0.32%. Miniso's stock dropped nearly 15%, with the company's first-quarter profit at 417 million yuan, a 29% decrease year-on-year [1] - Hong Kong stocks have shown a strong upward trend this year, attracting significant interest from A-share fund managers, particularly in new technology, new consumption, and pharmaceutical sectors [1] - Morgan Stanley analysts believe that Hong Kong stocks have high allocation value in the medium to long term, despite the need to monitor fluctuations in overseas markets and domestic demand [1] Group 2 - Yu Huan, managing the Great Wall Health Consumption Fund, emphasizes the importance of monitoring industries with improved competitive landscapes and low valuations in Hong Kong's tech and consumer sectors [2] - The Hong Kong stock market has become the best-performing tech market globally this year, driven by solid fundamentals and low valuations, with southbound funds being the main source of buying [2] - The Hong Kong IPO market is expected to see a significant recovery in 2025, providing a crucial window for domestic companies to raise foreign capital [2] Group 3 - CITIC Securities reports that the recent surge in A-share companies going public in Hong Kong is driven by strategic overseas expansion, regulatory conveniences, and improved liquidity in the Hong Kong market [3] - The Hong Kong government has implemented several supportive policies to enhance market liquidity and attractiveness, including lowering stamp duties and optimizing trading mechanisms [3] - The appeal of dividend assets in the Hong Kong market is expected to grow due to anticipated reforms and improvements in international liquidity, making them attractive for medium to long-term investments [3]

5月份，增量政策可能不多，但储备政策不少，政策定力仍然很强，目标是应对关税的冲击。因此，市 场在度过业绩风险后仍然会关注科技成长主题。内需相关板块仍会是国内政策的首要着力点，低利率环 境下业绩稳定的高股息板块仍有配置价值。除此以外，在可能出现的关税缓和过程中，那些品牌力强、 定价能力强、替代难度大的公司有望迎来估值的修复。 谭小兵：看好有边际变化的成长股 4月份市场呈现V字形走势，内需与红利好于成长股。展望5月份，进入业绩真空期，市场对指数填补之 后能否继续上攻还是存在分歧，个人相对还是偏乐观：一方面是国内政策会逐步兑现；另一方面中美谈 判或拉开序幕，这有利于修复市场的风险偏好。方向上看好有边际变化的成长股。 回顾4月，美国"对等关税"来袭，全球市场剧烈波动，就中国资产来看，月内A股和港股主要指数收 跌。进入5月，尽管外部不确定性因素依然存在，但中美关税谈判窗口有望来临，国内一揽子增量政策 也在加速落地，为国内股市稳定发展带来有力支撑。 展望后市，市场将会如何演绎？哪些投资机会值得关注？一起来看看长城基金权益基金经理们的观点吧 ~ 杨建华：持续关注关税政策 展望5月，关税政策及中美贸易谈判仍将会成为左右市场的 ...

Group 1 - The market is expected to continue its oscillation in the short to medium term, with accelerated style rotation driven by monetary policy easing and strong export performance [1] - In May, a rotation pattern of "risk aversion - consumption - growth" may re-emerge, starting with technology growth stocks, followed by a shift towards defensive assets as macroeconomic risks increase [1] - The recovery of the consumption sector is anticipated after the defensive phase, supported by policy dividends and improving consumption data, leading to new investment opportunities driven by domestic demand [1] Group 2 - The market shows resilience due to dual drivers of policy support and economic recovery, despite short-term fluctuations in trading volume reflecting cautious sentiment [2] - The first quarter saw a positive turnaround in net profit growth for all A-shares, indicating improving corporate earnings and strengthening internal economic recovery [2] - The effects of monetary policy easing and long-term capital inflows are expected to enhance liquidity, supporting a continued recovery in consumption and investment sectors [2]